Global Gene Therapy for Inherited Genetic Disorders Market 2019-2023

The global gene therapy for inherited genetic disorders market size will grow by USD 5.81 billion during 2019-2023. This report provides a detailed analysis of the market by application (eye disorders, hematological disorders, central nervous system disorders, muscular disorders, and others) and geography (Asia, Europe, North America, and ROW). The report analyzes the market’s competitive landscape and offers information on several gene therapy drug manufacturers for inherited genetic disorders including BioMarin Pharmaceutical Inc., bluebird bio Inc., Novartis AG, Orchard Therapeutics Plc, and Spark Therapeutics Inc.

Some of the key findings from our gene therapy for inherited genetic disorders market forecast report are summarized below

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a FREE sample now!

Global gene therapy market for inherited genetic disorders: Industry overview

Gene therapy has the potential to cure inherited diseases that cannot be cured using conventional drugs. It is being increasingly adopted in clinical trials because of its high efficacy and safety towards the treatment of inherited genetic disorders. For instance, LUXTURNA, an AAV-based gene therapy is used for the treatment of biallelic RPE65 mutation associated retinal dystrophy. Similarly, Strimvelis, an ex vivo stem cell gene therapy is indicated as a single treatment for patients with ADA-severe combined immunodeficiency. The high efficacy and safety offered by gene therapy will increase the preference for gene therapy treatments for inherited genetic disorders, subsequently driving gene therapy for inherited genetic disorders market growth during the forecast period.

Additionally, upcoming gene therapy for inherited genetic disorders market trends such as the increase in strategic alliances among vendors will also influence the growth of this global market. Vendors in this market are focusing on entering into partnerships to capitalize on the growing demand for curative gene therapies. Merck KGaA and GenScript Biotech Corp. recently formed an alliance to focus on the manufacturing of plasmid and viral vector in China. Many such alliances among vendors will result in the development of novel gene therapies for patients with inherited genetic disorders. As a result of these factors, the global gene therapy for inherited genetic disorders market size will grow at a CAGR of 189%. However, the market’s momentum will decelerate in the coming years because of the decrease in year-over-year growth.

Top gene therapy companies for inherited genetic disorders covered in this market research report

The global gene therapy for inherited genetic disorders market is highly concentrated. This research report provides a detailed analysis of the market’s competitive landscape and provides information on the products offered by various companies. Key insights provided by this gene therapy for inherited genetic disorders market report will help companies create effective strategies to improve their revenue share.

The report offers a detailed analysis of several leading companies including:

• BioMarin Pharmaceutical Inc.
• bluebird bio Inc.
• Novartis AG
• Orchard Therapeutics Plc
• Spark Therapeutics Inc.

Gene therapy for inherited genetic disorders market segmentation based on application

• Eye disorders
• Hematological disorders
• Central nervous system disorders
• Muscular disorders
• Others

Gene therapy was mainly adopted for the treatment of genetic eye disorders in 2018. With the increasing prevalence of hematological disorders across the world, the adoption of gene therapy will increase in hematological disorders applications and this segment will account for the largest market share by the end of the forecast period.

Gene therapy for inherited genetic disorders market segmentation based on geography

• Asia
• Europe
• North America
• ROW

North America will provide maximum growth opportunities for companies in the gene therapy for inherited genetic disorders market. Vendors in the region are developing drugs for inherited genetic disorders that are in the final stages of clinical trials and are expected to be launched during the forecast period. This coupled with the availability of installment-based reimbursement model will contribute to the growth of gene therapy for inherited genetic disorders market growth in North America.

Key highlights of the global gene therapy for inherited genetic disorders market for the forecast period 2019-2023

• CAGR of the market during the forecast period 2019-2023
• Detailed information on factors that will accelerate the growth of the gene therapy for inherited genetic disorders market during the next five years
• Precise estimation of the global gene therapy for inherited genetic disorders market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the gene therapy for inherited genetic disorders industry across Asia, Europe, North America, and ROW
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive details of factors that will challenge the growth of gene therapy companies for inherited genetic disorders 

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch